Peroxisome Proliferator-Activated Receptor-γ Agonists Suppress Adrenocortical Tumor Cell Proliferation and Induce Differentiation | Zendy

Matthias Johannes Betz | Zendy; I Shapiro | Zendy; Martin Faßnacht | Zendy; Stefanie Hahner | Zendy; Martín Reincke | Zendy; Felix Beuschlein | Zendy

Open Access

Peroxisome Proliferator-Activated Receptor-γ Agonists Suppress Adrenocortical Tumor Cell Proliferation and Induce Differentiation

Author(s) -

Matthias Johannes Betz,

I Shapiro,

Martin Faßnacht,

Stefanie Hahner,

Martín Reincke,

Felix Beuschlein

Publication year - 2005

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2004-1267

Subject(s) - peroxisome proliferator activated receptor , adrenocortical carcinoma , context (archaeology) , cancer research , receptor , endocrinology , cell growth , medicine , biology , biochemistry , paleontology

Thiazolidinediones (TZDs) have been implemented into clinical practice for the treatment of type 2 diabetes mellitus as specific peroxisome proliferator-activated receptor (PPAR)-gamma ligands. Moreover, recent evidence has suggested that TZDs might have favorable effects in the treatment of a variety of tumors as differentiation-inducing agents. Adrenocortical carcinoma (ACC) is a rare tumor entity with poor prognosis due to its highly malignant phenotype and lack of effective treatment options.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research